Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71904 | 1.00 | NR1H2 (0.45) | NR1H2POLBL3MBTL1HSD17B10CHRM2 | |
| SCHEMBL283443 | 1.00 | NR1H2 (0.45) | NR1H2POLBL3MBTL1HSD17B10CHRM2 | |
| SCHEMBL133363 | 0.90 | L3MBTL1 (0.58) | NR1H2POLBL3MBTL1HSD17B10HPGD | |
| SCHEMBL47049 | 0.90 | L3MBTL1 (0.58) | NR1H2POLBL3MBTL1HSD17B10HPGD | |
| SCHEMBL135177 | 0.90 | L3MBTL1 (0.58) | NR1H2POLBL3MBTL1HSD17B10HPGD | |
| SCHEMBL282976 | 0.88 | POLB (0.51) | NR1H2POLBL3MBTL1HSD17B10HPGD | |
| SCHEMBL192841 | 0.88 | POLB (0.51) | NR1H2POLBL3MBTL1HSD17B10HPGD | |
| SCHEMBL282977 | 0.88 | POLB (0.51) | NR1H2POLBL3MBTL1HSD17B10HPGD | |
| Hydrochloric Acid SCHEMBL5780709 | 0.87 | HSD17B10 (0.37) | NR1H2POLBL3MBTL1HSD17B10HPGD | |
| SCHEMBL5785055 | 0.87 | NR1H2 (0.37) | NR1H2POLBL3MBTL1HSD17B10ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BIOGEN MA INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | disclosed |
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025226892-A1 | SPIROCYCLE-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4606377-A2 | NOVEL AMINO PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2025-08-27 | — | — | EP | disclosed |
| EP-4605400-A1 | NOVEL TRIHETEROCYCLIC COMPOUNDS | Idience Co., Ltd. (KR) | 2025-08-27 | — | — | EP | disclosed |
| EP-4236937-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4580620-A2 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS, COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Hager Biosciences, LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-0934308-A1 | 3-PYRIDYLOXYMETHYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1999032480-A1 | HETEROCYCLIC ETHER AND THIOETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5914328-A | CONTROL DOPAMINE RELEASE, ACTIVATE CHOLINERGIC CHANNELS | ABBOTT LABORATORIES (US) | 1999-06-22 | — | — | US | disclosed |
| WO-1998025920-A1 | 3-PYRIDYL ENANTIOMERS AND THEIR USE AS ANALGESICS | ABBOTT LABORATORIES (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0846114-A1 | 3-PYRIDYLOXYALKYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997046554-A1 | 3-PYRIDYLOXYMETHYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1997-12-11 | — | — | WO | disclosed |
| US-5629325-A | TREATMENT OF NERVOUS SYSTEM DISORDERS; NEURONAL NICOTINIC CHOLINERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-05-13 | — | — | US | disclosed |
| WO-1996040682-A1 | 3-PYRIDYLOXYALKYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 1996-12-19 | — | — | WO | disclosed |
| US-4902684-A | Benzazepine and benzothiazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1989012633-A1 | BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | E.R. SQUIBB & SONS, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BTK, LYN, SYK | NR1H2 1467/4885POLB 3257/4885L3MBTL1 1341/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | NR1H2 2552/4885POLB 2293/4885L3MBTL1 412/4885 |
| US-20250353864-A1 | INDAZOLE CONTAINING MACROCYCLES AND THEIR USE | AADAC, PAICS, CYP3A43 | NR1H2 1691/4885POLB 1940/4885L3MBTL1 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.